In Colorado, miRagen Therapeutics, a biopharmaceutical company which develops microRNA-targeting therapies for treating diseases and cancer, has acquired Signal Genetics. The acquisition was funded partly by a $40 million investment by Fidelity Management and Research Company, Brace Pharma Capital, Atlas Venture, Boulder Ventures, JAFCO Co., Ltd., MP Healthcare Venture Management, MRL Ventures (Merck), Remeditex Ventures, and others. Signal Genetics, a publicly traded company based in California, has been working on genetic testing technology for multiple myeloma. Signal’s name and stock symbol will be changed to that of miRagen Therapeutics, as miRagen acquired 96% of Signal’s stock. Signal’s executives and directors will all resign as part of the acquisition.
Latest article
Starbucks disappointed in Cali compostable cup trial
In California, Starbucks is winding down a compostable cups trial following disappointing results. The fiber-based cups, which the coffee giant began trialing in West...
Funding shortfall forces NovoNutrients to launch asset sale
In California, gas fermentation firm NovoNutrients has ceased operations and is looking for a buyer for its assets, citing difficulty securing sufficient funding.
The...
Mara Renewables secures $9.1M to boost Omega-3 DHA
In Canada, Mara Renewables has received US$9.1 million from S2G Investments to expand R&D and capacity for its algae-based omega‑3 DHA platform.
The vital...